Opinion
Video
Insights and Challenges in Advancing HER2+ Breast Cancer Care
Experts review groundbreaking advancements in HER2+ breast cancer treatment, covering curative strategies, metastatic challenges, and the need for ongoing innovation to enhance patient outcomes.
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
The panel concludes the discussion on HER2-positive breast cancer treatment, emphasizing significant advances in adjuvant, neoadjuvant, and metastatic settings. Isaacs highlights exploring chemotherapy-free regimens for hormone receptor-positive, HER2-positive patients. Sharma underscores the need for further optimization in endocrine therapy and CDK4/6 inhibitor studies. McArthur expresses excitement about the unprecedented era of successful drug development, focusing on brain metastasis and leptomeningeal disease. The importance of enrolling patients in clinical trials is emphasized. Rugo discusses individualizing neoadjuvant therapy and potential strategies for trastuzumab deruxtecan (T-DXd) maintenance. O’Shaughnessy addresses the challenge of treating de novo metastatic cases and the necessity for chronic therapies. The panel collectively advocates for ongoing research and patient-centric care. The discussion provides valuable insights into the evolving landscape of HER2-positive breast cancer treatment.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
